A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

NCT00127127 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors

Interventions

DRUG: vorinostat

Sponsor

Merck Sharp & Dohme LLC